InfuSystem Reports Q3 2026 Revenue Growth Driven by Patient Services
InfuSystem (INFU) reported third-quarter 2026 net revenues of $37.6 million, a 3% increase year-over-year. The growth was primarily fueled by the Patient Services segment, which saw a 15.4% rise to $25.8 million due to increased treatment volumes in Oncology and Wound Care. Notably, Wound Care revenue surged by 112%, reflecting rapid scaling of compression therapy product lines. While Device Solutions revenue declined by 16.6% following the restructuring of a GE Healthcare contract, pro-forma revenue growth accelerated to 10.2%. The company also demonstrated improved profitability, with net income rising to $3.2 million ($0.15 per diluted share) and Adjusted EBITDA increasing 12.5% to $9.4 million. Management reaffirmed full-year pro-forma revenue growth guidance of 6% to 8%.
Topics: earnings report gross margin revenue growth segment performance